Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

Real-World Analysis Confirms Efficacy/Safety of Dostarlimab Plus Chemotherapy in Advanced Endometrial Cancer

March 17th 2025

Findings from a real-world study confirm the efficacy and safety of dostarlimab plus chemotherapy in advanced endometrial cancer.

Frontline Maintenance With Niraparib Plus Bevacizumab Is Active in Advanced Ovarian Cancer

March 16th 2025

Frontline maintenance with niraparib and bevacizumab showed efficacy and safety profiles that are in line with similar regimens in advanced ovarian cancer.

Updated MIRASOL Data Support Mirvetuximab Soravtansine as SOC for FRα+ Platinum-Resistant Ovarian Cancer

March 16th 2025

Mirvetuximab soravtansine continued to showcase superior OS, PFS, ORR, & DOR benefits over chemotherapy in FRα-positive platinum-resistant ovarian cancer.

Cadonilimab Plus Lenvatinib Proves Active in Platinum-Pretreated, Advanced Endometrial Cancer

March 15th 2025

Cadonilimab plus lenvatinib showed promise as therapy for patients with advanced endometrial cancer and disease progression on prior platinum therapy.

Nivolumab Yields High Clinical CR Rates Allowing for Surgery Omission in dMMR/MSI-H Endometrial Cancer

March 15th 2025

Nivolumab elicited PR/CRs in all patients treated with resectable dMMR endometrial cancer and no patients experienced disease recurrence during follow-up.

Retifanlimab Adds FDA-Approved Option to Merkel Cell Carcinoma Treatment Landscape

March 14th 2025

Retifanlimab demonstrated durable activity with a tolerable safety profile in patients with chemotherapy-naive MCC.

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

March 14th 2025

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Investigators Focus on Reducing On-Target, Off-Tumor Toxicities With CAR T-Cell Therapy in Solid Tumors

March 14th 2025

Renier Brentjens, MD, PhD, details solid tumors his laboratory is investigating CAR T-cell therapy in and ways to mitigate on-target, off-tumor toxicities.

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

March 13th 2025

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

March 13th 2025

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

March 13th 2025

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Investigators Are Making Headway Bringing CAR T-Cell Therapy to Solid Tumors

March 12th 2025

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer

March 10th 2025

T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.

Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC

March 10th 2025

Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.

Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment

March 10th 2025

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer

March 9th 2025

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options

March 7th 2025

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer

March 7th 2025

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

BTK Degraders May Be a Promising Approach in CLL/SLL for Patients With Disease Progression

March 6th 2025

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.